Affiliations: Department of Urology, The Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Hangzhou, Zhejiang, China
Correspondence:
[*]
Corresponding author: Yu-Yong Wang, Department of Urology, The Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, 261 Huansha Road, Hangzhou 310006, China. Tel.: +86 0571 56007402; Fax: +86 0571 56005600; E-mail:[email protected]
Abstract:
BACKGROUND: Adrenomedullin levels in the peripheral blood are
associated with prognosis of some cancers. Intermedin is structural
similarities to adrenomedullin. OBJECTIVE: The current study aimed to investigate the prognostic
value of plasma intermedin levels for progression and distant metastasis in
prostate cancers. METHODS: This study included 218 patients undergoing radical
prostatectomy for localized prostatic cancer and 218 age-matched healthy
men. Plasma intermedin levels were measured using radioimmunoassay. The
relationships between plasma intermedin levels and 5-year progression and
5-year distant metastasis were evaluated using a multivariate analysis. RESULTS: Plasma intermedin levels were markedly higher in all
patients than in healthy men. Patients with Gleason score ≥ 7, tumor
node metastasis stage T2, organ unconfined, present extra-prostatic
extension, seminal vesicle invasion or positive lymph node had higher
intermedin levels. Intermedin was identified as a prognostic predictor for
5-year progression and 5-year metastasis. Under receiver operating
characteristic curves, intermedin had high predictive values for 5-year
progression and 5-year metastasis. CONCLUSIONS: Elevated plasma intermedin levels are independently
associated with long-term recurrence and distant metastasis of prostate
cancer and intermedin has potential to be a prognostic predictive biomarker
for prostate cancer.
